Acceleron Pharma

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials.


Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2004
Size (employees)
121 (est)+19%
Acceleron Pharma was founded in 2004 and is headquartered in Cambridge, US

Key People at Acceleron Pharma

Habib Dable

Habib Dable

President and Chief Executive Officer
Kevin McLaughlin

Kevin McLaughlin

Chief Financial Officer
Steven Ertel

Steven Ertel

Chief Operating Officer
Matthew Sherman

Matthew Sherman

Chief Medical Officer
Ravi Kumar

Ravi Kumar

Chief Scientific Officer
John Quisel

John Quisel

SVP, Business Development and General Councel
Christopher Rovaldi

Christopher Rovaldi

VP, Program Management

Acceleron Pharma Office Locations

Acceleron Pharma has an office in Cambridge
Cambridge, US (HQ)
128 Sidney Street

Acceleron Pharma Metrics

Acceleron Pharma Financial Metrics

Revenue (2016)

$27.8 m

Revenue growth (2015-16), %

53%

Net income (2016)

($57 m)

Market capitalization (21-Mar-2017)

$1.1 b

Closing share price (21-Mar-2017)

$28

Cash (31-Dec-2016)

$21 m
Acceleron Pharma's current market capitalization is $1.1 b.
Acceleron Pharma's revenue was reported to be $27.8 m in FY, 2016 which is a 53.5% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$57.2 m$14.6 m$18.1 m$27.8 m

Revenue growth, %

(74%)24%53%

Operating expense total

$50.3 m$70.1 m$79 m$93.9 m

EBIT

$7 m($55.5 m)($60.9 m)($66.1 m)

EBIT margin, %

12%(379%)(336%)(238%)

Interest expense

$2.1 m$922 k

Interest income

$39 k$83 k$512 k$1.9 m

Pre tax profit

($57 m)

Income tax expense

($24 k)

Net Income

($21.9 m)($51.3 m)($63.9 m)($57 m)
Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

$34.9 m$65 m$39.6 m$113.2 m$176.5 m$27.8 m$21 m

Accounts Receivable

Inventories

$2.2 m$2.5 m$2.5 m$3.9 m

Current Assets

$119 m$182.3 m$110.9 m$146.8 m

PP&E

$3.7 m$3.1 m$3.1 m$5.2 m

Total Assets

$123.7 m$186.3 m$146.3 m$247.6 m

Accounts Payable

$885 k$724 k$875 k$1.6 m

Current Liabilities

$27.2 m$9.3 m$14.5 m$16.1 m

Additional Paid-in Capital

$250.1 m$399.8 m$416.9 m$590.5 m

Retained Earnings

($192.3 m)($243.6 m)($307.5 m)($364.5 m)

Total Equity

$57.8 m$156.3 m$109.3 m$225.6 m

Financial Leverage

2.1 x1.2 x1.3 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($21.9 m)($51.3 m)($63.9 m)($57 m)

Depreciation and Amortization

$915 k$1.1 m$1.2 m$1.7 m

Accounts Receivable

Inventories

($823 k)($255 k)$7 k($1.4 m)

Accounts Payable

($53 k)($161 k)$151 k$644 k

Cash From Operating Activities

($19.7 m)($53.2 m)($44.2 m)($44.7 m)

Purchases of PP&E

($307 k)($514 k)($959 k)($3.4 m)

Cash From Investing Activities

($307 k)($514 k)($109 m)($108.8 m)

Long-term Borrowings

($3.7 m)($16.3 m)

Cash From Financing Activities

$93.5 m$117 m$4.5 m$146.7 m

Interest Paid

$1.7 m$1.6 m

Acceleron Pharma Operating Metrics

FY, 2015FY, 2016

Ongoing Phase III Programs

22

Acceleron Pharma Market Value History

Acceleron Pharma Online Presence

Acceleron Pharma Company Life

You may also be interested in